TBPH Theravance Biopharma Inc.

27.2
+1.06  (+4%)
Previous Close 26.14
Open 26.33
Price To Book -8.45
Market Cap 1,543,934,750
Shares 56,762,307
Volume 398,180
Short Ratio
Av. Daily Volume 304,441
Stock charts supplied by TradingView

NewsSee all news

  1. Theravance Biopharma Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference

    DUBLIN, Jan. 7, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines,

  2. Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program

    DUBLIN and NEW YORK, Dec. 23, 2019 /PRNewswire/ -- Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (NASDAQ:TBPH) ("Theravance Biopharma") and Pfizer Inc. (NYSE:PFE)

  3. Theravance Biopharma Announces Dosing of First Patient in Phase 2 Allergen Challenge Study of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases

    DUBLIN, Dec. 3, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 2 allergen challenge study of

  4. Theravance Biopharma to Present at Two Upcoming Investor Conferences

    DUBLIN, Nov. 26, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) announced today that management will participate in fireside chats at two upcoming investor conferences:

  5. Theravance Biopharma to Present at the 2019 Credit Suisse Healthcare Conference

    DUBLIN, Nov. 6, 2019 /PRNewswire/ -- November 6, 2019 – Theravance Biopharma, Inc. (NASDAQ:TBPH) announced today that management will participate in a corporate presentation at the 28th Annual Credit Suisse Healthcare

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data released September 20, 2017 - primary endpoint met.
Closed Triple - IMPACT
COPD
Approved June 21, 2013.
VIBATIV (telavancin hydrochloride) for injection
Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP)
Approved April 30, 2015.
BREO ELLIPTA
Asthma
Phase 3 data due 2H 2020.
Ampreloxetine (TD-9855)
nOH
sNDA filing announced October 2, 2019.
Closed Triple - CAPTAIN
Asthma
Approval announced September 19, 2017.
Closed Triple
COPD
FDA Approval announced November 9, 2018.
Revefenacin
COPD
Phase 2b data released August 2, 2017. Primary endpoint not met.
Velusetrag (TD-5108)
Gastroparesis
Phase 2 data released June 2016
TD-6450
Hepatitis C virus (HCV)
Phase 3 trial discontinued following recent interim analysis.
Telavancin
Bacteremia
Phase 3 first patient enrolled late February 2015. Data due 2017
Telavancin
Staphylococcus aureus bacteremia
Phase 2 data due late-2020.
TD-1473
Crohn's Disease
Phase 2b data due late-2020.
TD-1473
Ulcerative Colitis
Phase 1 Part C data due mid-2020.
TD-8236
Asthma
Phase 2 data due 2020.
TD-8236
Asthma

Latest News

  1. Theravance Biopharma Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference

    DUBLIN, Jan. 7, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines,

  2. Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program

    DUBLIN and NEW YORK, Dec. 23, 2019 /PRNewswire/ -- Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (NASDAQ:TBPH) ("Theravance Biopharma") and Pfizer Inc. (NYSE:PFE)

  3. Theravance Biopharma Announces Dosing of First Patient in Phase 2 Allergen Challenge Study of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases

    DUBLIN, Dec. 3, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 2 allergen challenge study of

  4. Theravance Biopharma to Present at Two Upcoming Investor Conferences

    DUBLIN, Nov. 26, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) announced today that management will participate in fireside chats at two upcoming investor conferences:

  5. Theravance Biopharma to Present at the 2019 Credit Suisse Healthcare Conference

    DUBLIN, Nov. 6, 2019 /PRNewswire/ -- November 6, 2019 – Theravance Biopharma, Inc. (NASDAQ:TBPH) announced today that management will participate in a corporate presentation at the 28th Annual Credit Suisse Healthcare

  6. Theravance Biopharma to Present at the 2019 Cantor Global Healthcare Conference

    DUBLIN, Sept. 25, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) announced today that management will participate in a fireside chat at the 2019 Cantor Global Healthcare Conference on Thursday, October 3,

  7. Theravance Biopharma Reports Positive Results from Phase 1 Clinical Trial of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases

    DUBLIN, Sept. 9, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) ("Theravance Biopharma" or the "Company") today announced initial results, including positive biomarker responses, from its

  8. Theravance Biopharma to Present at Two Upcoming Investor Conferences

    DUBLIN, Aug. 28, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) announced today that members of management will participate in fireside chats at two upcoming investor conferences: 14th Annual Wells Fargo